Introduction
In renal transplantation, the occurrence of one or more episodes of acute allograft rejection (AAR) is a major determinant of graft survival [1] . Most episodes of AAR are caused by cell-mediated processes and require the infiltration of alloactivated T cells into the engrafted organ. These cells are characterized by the expression of surface markers indicating a memory (CD45ROq) anduor activated (CD25q) phenotype [2, 3] , which develop subsequent to T-cell receptor (TCR) interactions with MHC-alloantigen complexes or donor MHC in secondary lymphoid tissue [4] . A further result of this process is the expression of chemokine receptors that direct the trafficking of alloactivated T cells into the graft in response to local production of chemokines, initially by resident cells. There is now deep interest in this area that reflects the recent identification of restricted chemokine-receptor interactions as key functional events in T-cell recruitment and potential therapeutic targets for the prophylaxis of AAR. We discuss this recent evidence and how it relates to our current knowledge of chemokine-receptor expression in human renal transplantation.
T-cell trafficking
The migration of T cells to extravascular sites requires the successful completion of a series of co-ordinated molecular interactions. These processes are common to all trafficking leukocytes [5, 6] . First, leukocytes marginated (usually in post-capillary venules) by flow dynamics, roll through transient association and dissociation between glycosylated and sialylated ligands and endothelial cell (EC) surface expressed selectins. This allows leukocytes to sample the EC surface microenvironment where high concentrations of chemokines are sequestered. Chemokines are a superfamily of small proteins that direct leukocyte migration and position [7] . They bind G-protein linked counter-receptors (chemokine receptors) on the leukocyte cell surface to trigger intracellular signalling cascades that rapidly promote the activation of leukocyte integrins such as LFA-1 and VLA-4. Integrins then facilitate firm leukocyte adhesion by binding to super-immunoglobulin counter-receptors (e.g. ICAM-1, VCAM-1) expressed on EC. Adhered cells then transmigrate, across EC junctions and into the extracellular matrix, by directed movement along chemotactic and haptotactic gradients of chemokines and adhesion molecules. In vivo, intravascular flow may be central for this process, as adhered T cells traffic in response to adequate chemokine signals transmitted at pro-migratory (cell contact) zones within a milieu of continuous application of shear flow [8, 9] . This process has been termed chemorheotaxis.
T-cell subsets express different patterns of chemokine receptors that modulate recruitment to different organ sites in physiological and inflammatory states. For example, naïve (CD45RAq, CD25À) T cells display chemokine receptors that, on ligation by constitutive chemokines expressed by high endothelial venules, direct their preferential trafficking to secondary lymphoid tissue [10] . At these sites, recruited T cells may encounter antigens, which trigger and sustain T-cell activation. These cells then proliferate into activated (effector) and memory cells and their migratory phenotype changes to one responsive to signals from inducible chemokines produced in inflamed organs. This phenotype may reflect the origin of the antigen encountered and allows T cells to target specific environments in response to local chemotactic signals. For example, the chemokine receptor CCR4 is expressed on a subset of T cells with memory for skin and intestinal antigens and promotes trafficking to skin (in cells co-expressing the E selectin ligand cutaneous lymphocye antigen) and to intestinal mucosa (in cells co-expressing high levels of the integrin a4b7), respectively [11] . A ligand for CCR4, the chemokine TARCuCCL17, is preferentially expressed in inflamed skin.
Over 40 inducible chemokines and 20 inducible chemokine receptors have been identified to date [12] . In vitro studies on the responses of activated T cells to inflammatory chemokines suggest substantial redundancy in this system, with multiple chemokines produced at tissue sites binding to multiple receptors on circulating leukocytes [13] . Further, mice with functional deletions in single genes that encode inducible chemokines or their receptors only show mild alterations in defensive functions [14 -17] . However, there is now increasing evidence of tight specificity of chemokine receptors in defined inflammatory states with deployment of different subsets of cells under firm control. Recent studies show that expression of multiple chemokine receptors allow navigation by leukocytes in a systematic fashion through arrays of multiple chemokines [18] so different chemokine receptor pairs may be necessary for activation, transmigration, tissue migration and retention, respectively. Disease models in knockout mice are now further confirming key roles for individual chemokines and their receptors (see below).
Chemokines and their receptors in human renal transplantation
There have now been studies on the expression of a number of chemokines and chemokine receptors in human renal transplantation that show their increased expression in AAR (see Table 1 and below). Most of these chemokine-receptor combinations are mononuclear cell targeted or expressed. Detailed reviews of the biology of these molecules have been published elsewhere [12] . Until recently, the significance of these ex vivo studies was difficult to ascertain as both resident renal cells and infiltrating cells are promiscuous sources of chemokines [12, [19] [20] [21] , and the proinflammatory cytokines that promote their production in vitro are present in the kidney in inflammation in vivo [3] . However, studies in organ transplantation models in knockout animals and with blocking antibodies are now clarifying these observations (see below and Tables 2 and 3 ). These indicate key roles for the receptors CXCR3 and CCR5 and selected targeting chemokines.
The biology of CXCR3 and CCR5
Studies in patients with rheumatoid arthritis first showed that CXCR3 and CCR5 are of particular importance in the recruitment of activated and memory T cells to inflammatory sites in human inflammation [22] . These receptors are also preferentially expressed on Th1 cells, the dominant Th phenotype in AAR and other cell-mediated immune processes [23] . For CXCR3, virtually all T cells at sites of non-renal human inflammation with prominent mononuclear cell infiltrates are receptor positive. CXCR3 is expressed by up to 40% of freshly isolated peripheral blood T cells, but will only mediate adhesion under conditions of flow and cell migration towards targeting chemokines after cell activation [24, 25] . CXCR3 is ligated by the inflammatory non-ELR CXC chemokines CXCL10uIP-10, CXCL9u
Mig and CXCL11uI-Tac [25] [26] [27] , which are differentially produced by multiple cell types, including EC, on activation by IFN-g and TNF-a in combination.
The expression of CCR5 is closely linked to CXCR3; all T cells that express CCR5 are also CXCR3q, indicating that these cells may be chemoattracted through either receptor [22] . CCR5 is ligated by RANTESuCCL5, MIP-1auCCL3 and MIP-1buCCL4 to promote the chemoattraction of activated T cells in chemotactic assays [28, 29] . Also, analogous with CXCR3, there is little chemoattraction of unstimulated lymphocytes by chemokines active against CCR5. Studies on the chemotactic potential of the supernatant from activated (IFN-g and TNF-a treated) PTEC, which is chemokine rich, towards CD3q T cells confirm this. There is little chemotactic activity towards freshly isolated T cells; however, after activation by TCR ligation and IL-2 treatment there is heavy cell migration. Most of this chemotaxis is mediated through CXCR3 and CCR5, with an additional role for CX3CR1, the CX3CL1ufractalkine receptor [30] .
Animal models for CXCR3 and CCR5 and their ligands
In a rat cardiac transplant model, where pre-transplant MHC priming resulted in allograft rejection, there was increased intragraft expression of CXCL10uIP-10 and CXCL9uMig and infiltration with mononuclear cells expressing CXCR3 [31] . In a murine cardiac model, Kapoor and colleagues [32] showed that both CXCL10uIP-10 and CXCL9uMig expression was increased from day 2 until the day of rejection (day 8-10) although the infiltrating cellular phenotype was not assessed. In MHC disparate skin allografts, blocking of CXCL9uMig inhibited T-cell and macrophage migration into the graft [33] . Injection of CXCL9uMig then restored T-cell infiltration and subsequent rejection. Hancock and colleagues [34] showed early CXCL10u IP-10 production (at day 1) by EC in cardiac allografts and isografts, presumably as a result of surgical manipulation and reperfusion injury. There was subsequent amplified expression of CXCL10uIP-10 and sequential expression of CXCL9uMig and CXCL11uI-Tac in allografts but not isografts [34] . Transplanting cardiac allografts from CXCL10uIP-10 knockouts into wildtype animals had a dramatic effect, with no subsequent development of AAR. This indicates a key role for early induction of CXCL10uIP-10 promoting subsequent production of CXCL9uMig and CXCL11uI-TAC and the recruitment of alloactivated T cells. The development of this 'chemokine cascade' may be dependent on early natural killer (NK) cell recruitment; EC-expressed CXCL10uIP-10 may ligate NK cell CXCR3 to localize these cells within the graft, where they recognize disparate MHC on the surface of EC and other resident cells. Production of IFN-g and other cytokines by NK cells may then amplify CXCL10uIP-10 production and promote sequential expression of CXCL9uMig and CXCL11uI-TAC with subsequent recruitment of alloactivated T cells. This is consistent with recent data showing early infiltration of NK cells (by day 1) in a separate animal model of cardiac transplantation [35] and induction of chemokines by resident cells before infiltration of mononuclear cells in an animal model of lupus nephritis [36] .
Studies using knockout animals complement these findings, with a mean cardiac allograft survival of 58 days in CXCR3ÀuÀ compared with 7 days in the wild-type (CXCR3quq) [37] . This increased survival was consistent with the histology of the graft, which showed greatly decreased cellular infiltrate and damage compared with controls. Similar effects on graft survival were obtained using an anti-CXCR3 antibody in CXCR3quq recipients. Transplantation models for CCR5 knockouts show less dramatic results but are still highly significant. MHC disparate cardiac allografts transplanted into CCR5ÀuÀ mice show a tripling of graft survival, and addition of low-dose cyclosporin results in permanent allograft survival [38] . This demonstrates an important principle for the prophylaxis of AAR; increasing the threshold for T-cell infiltration may dramatically lower the doses of immunosuppression required. However, whilst these models provide major evidence for a role for CXCR3 and CCR5 in AAR, in cardiac allografts chemokine expression in the heart is primarily by EC or infiltrating mononuclear cells, whereas kidneys have a heterogeneous population of resident cells, which express inflammatory chemokines when stimulated. Therefore, use of these knockout animals in studies on renal transplantation would help prove the applicability of this data to other organ systems. More focused ex vivo analyses on the role of CXCR3 in human renal transplantation are also required.
CXCR3 and CCR5 and their ligands in human renal transplantation
Despite the evidence for a role for CXCR3 and its ligands in AAR, there is relatively little data in human renal transplantation. In rejecting human lung allografts, infiltrating T cells express CXCR3 and these cells were highly responsive to CXCL10uIP-10, which was present in large quantities in bronchoalveolar lavage fluid of these patients [39] . Romagnani and colleagues [61] have found infiltrating cells expressing CXCR3 in renal allograft rejection with the presence of ligating chemokines, although this data has not yet been published as a full manuscript.
There have been several studies on a role for CCR5 and its ligating chemokines. Segerer and colleagues [40] demonstrated that CCR5q cells are present in AAR and correlate with the distribution of T cells. Also, CCR5 mRNA localizes to infiltrating mononuclear cells in rejecting human allografts. Recently, Fischereder and colleagues [41] showed that renal transplant recipients homozygous for CCR5D32, a non-functioning mutant allele of CCR5 with a 32 bp deletion, have significantly longer graft survival than those patients with other genotypes. Interestingly, apart from high resistance of CCR5D32 homozygotes to HIV infection, these individuals show no obvious phenotype and are otherwise healthy. In the earliest study of chemokine expression in human renal AAR, Pattison and colleagues [42] demonstrated the presence of RANTESuCCL5 (a ligand for CCR5 and CCR1).
This chemokine was localized to infiltrating mononuclear cells, tubular epithelium and vascular endothelium; effectors of and targets for injury. More recently, Robertson and colleagues [43] showed predominant basolateral surface expression of CC chemokines in AAR, with significant variation in the levels of MCP-1uCCL and MIP-1buCCL4, but not RANTESuCCL5 and MIP-1auCCL3 between rejection grades.
CX3CL1ufractalkine
A further chemokine of potential importance in AAR is CX3CL1ufractalkine. Unlike virtually all other chemokines it has a membrane-anchoring domain [44] . In addition, CX3CL1ufractalkine is the only ligand for its targeting receptor (CX3CR1) shown to date. CX3CL1u fractalkine can promote chemotaxis via a shed soluble domain as well as adhesion when transmembrane bound. CX3CR1 is expressed by NK cells, monocytes and IL-2 activated CD8q T cells [45] . Recently, Haskell and colleagues [46] have shown that in CX3CR1ÀuÀ heterotopic MHC mismatched cardiac transplants there was no difference in graft survival between knockout and wild-type animals; however, on addition of low-dose cyclosporin there was a threefold increase in graft survival. In renal biopsies from patients with AAR we have shown expression of CX3CL1ufractalkine mRNA and protein (by EC and tubular epithelial cells) that correlates with infiltration of mononuclear cells [47] . Supernatant from activated PTEC has some soluble CX3CL1ufractalkine attributable chemotactic activity towards activated T cells [30] and in its transmembrane-bound form may have a role in the retention of mononuclear cells at tubular sites [48] .
Other chemokines and their receptors in AAR
Both CCR1 and CCR2 have been implicated in acute AAR, although to a significantly less degree than CXCR3 and CCR5. Mismatched heterotropic cardiac transplants survive twice as long in CCR1ÀuÀ mice compared with wild-type mice [49] . In recipients treated with low doses of cyclosporin or anti-CD4 monoclonal antibodies there was prolonged allograft survival and no development of chronic rejection. Two chemokines that ligate CCR1, RANTESuCCL5 and MIP1-buCCL4, have been demonstrated in AAR in human renal transplants [42, 43] . CCR2ÀuÀ recipients of cardiac allografts have a similar phenotype. The ligating chemokines for CCR2 are MCP-1uCCL2, MCP-2uCCL8, MCP-3uCCL7 and MCP-4uCCL13. In renal transplantation, the main role of these molecules may be in directing macrophage infiltration as predominant CCR2 expression is by this cell type; MCP-1uCCL2 and MCP-4uCCL13 expression in AAR in human renal transplants correlate with, and colocalize to, infiltrating macrophages [50, 51] . In vitro analyses also indicate that the major role of PTEC-derived MCP-1uCCL2 may be for monocytesu macrophage rather than T-cell recruitment [52] .
Schmouder and colleagues [53] used RT-PCR to study the expression of the CXC chemokine ENA-78u CXCL5 in acute renal transplant rejection. This is predominately a neutrophil-and monocyte-directed chemokine that targets the receptor CXCR2. They demonstrated increased transcripts of ENA-78u CXCL5 localized to epithelial cells in vivo with up-regulation of expression by human epithelial cells in vitro when stimulated by IL-1b. There is also heavy local expression of IL-8uCXCL8 (which targets CXCR1 and CXCR2) in other models of human renal inflammation [54] , and elevated levels of this chemokine have been identified in the urine of patients with AAR [55, 56] . However, there is little expression of the IL-8uCXCL8 receptors CXCR1 and CXCR2 on freshly isolated or activated T cells [57] , so these chemokines are unlikely to have a central role in directing T-cell infiltration. A potential role has also been identified for CXCR4, which is also expressed by infiltrating T cells; however, the biological relevance of this is uncertain as it is expressed by all circulating leukocytes and targeted by SDF-1uCXCL12, a constitutively expressed chemokine important for homeostatic trafficking [58] .
Conclusions
Although a number of chemokines and their receptors are up-regulated in AAR, recent studies indicate a key role for CXCR3 and CCR5. Assessment of the applicability of this data to renal transplantation requires further expression studies in humans and analyses of animal models of renal transplantation. If confirmatory, then targeting CXCR3 anduor CCR5-mediated processes in the first few days after transplantation may prevent the early recruitment of NK cells and alloactivated T cells whilst the graft is activated from donor factors and ischaemia re-perfusion injury. This directed approach might allow lower induction and maintenance immunosuppressive therapy and sustain long-term graft survival. Finally, whilst recent studies provide essential insights into the mechanisms that promote AAR, there is little known of the role of chemokines and their receptors in the development of chronic allograft nephropathy.
